Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CING
stocks logo

CING

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.370
-40.43%
--
--
-0.873
-16.03%
--
--
-0.530
-51.38%
Estimates Revision
The market is revising No Change the revenue expectations for Cingulate Inc. (CING) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 1.03%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+1.03%
In Past 3 Month
Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 12.00 USD with a low forecast of 8.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 12.00 USD with a low forecast of 8.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.940
sliders
Low
8.00
Averages
12.00
High
16.00
Current: 3.940
sliders
Low
8.00
Averages
12.00
High
16.00
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$17 -> $16
2025-11-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$17 -> $16
2025-11-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.
Roth Capital
NULL
to
Buy
upgrade
$10 -> $17
2025-10-14
Reason
Roth Capital
Price Target
$10 -> $17
2025-10-14
upgrade
NULL
to
Buy
Reason
Roth Capital raised the firm's price target on Cingulate to $17 from $10 and keeps a Buy rating on the shares. The FDA's acceptance of Cingulate's NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth's expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$11 -> $10
2025-08-20
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$11 -> $10
2025-08-20
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $10 from $11 but keeps a Buy rating on the shares. The firm's post-Q2 call with the company's management has further strengthened its conviction for CTx-1301 regulatory acceptance in October and potential approval by mid-2026, the analyst tells investors in a research note. Assuming the NDA receives acceptance with an assigned PDUFA date, Roth expects a slew of launch preparation activities focused on disseminating CTx-1301's value in the crowded ADHD market, the firm added.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$12 -> $11
2025-05-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$12 -> $11
2025-05-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $11 from $12 and keeps a Buy rating on the shares post the Q1 report. The firm says its discussions with management further bolstered its conviction for CTx-1301 application filing, which it expects to occur in Q3. Roth's base case assumes CTx-1301 FDA approval by Q4 of 2026 and launch by the first half of 2027.
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$75 → $60
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$75 → $60
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$20
2025-03-06
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$20
2025-03-06
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cingulate Inc (CING.O) is -1.24, compared to its 5-year average forward P/E of -8.63. For a more detailed relative valuation and DCF analysis to assess Cingulate Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.63
Current PE
-1.24
Overvalued PE
52.37
Undervalued PE
-69.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
12.36
Current PS
0.00
Overvalued PS
50.70
Undervalued PS
-25.99
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CING News & Events

Events Timeline

(ET)
2025-11-13
08:11:32
Cingulate Announces Q3 Net Loss of $7.3 Million Compared to $4.1 Million Last Year
select
2025-11-10 (ET)
2025-11-10
08:23:13
Cingulate Appoints Downey as Chief Commercial Officer to Oversee CTx-1301 Launch Preparation
select
2025-10-28 (ET)
2025-10-28
08:21:28
Cingulate Reveals Phase 3 Results for CTx-1301, Achieves Primary Endpoint
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-20Benzinga
Roth Capital Reaffirms Buy Rating on Cingulate, Reduces Price Target to $16

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
9.0
10-24NASDAQ.COM
INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading

  • Inhibrx Biosciences Surge: Inhibrx Biosciences (INBX) shares soared over 81% after positive Phase 2 trial results for ozekibart in treating advanced chondrosarcoma, alongside updates on other cancer treatment studies.

  • Femasys Gains: Femasys Inc. (FEMY) saw an 18% increase following the launch of a post-market clinical study for its FemBloc Permanent Birth Control, complying with EU regulations.

  • Cingulate's Presentation: Cingulate Inc. (CING) rose over 6% after announcing that data from its ADHD treatment candidate, CTx-1301, will be presented at the AACAP Annual Meeting, highlighting its potential in ADHD management.

  • Community Health Systems Performance: Community Health Systems, Inc. (CYH) shares increased over 4% after reporting positive Q3 results, contributing to a generally favorable after-hours trading environment for biotech stocks.

[object Object]
Preview
9.0
10-24Newsfilter
Cingulate's Top ADHD Candidate CTx-1301 Chosen for Podium Presentation at AACAP Annual Meeting

  • CTx-1301 Presentation: Cingulate Inc. announced that data from its ADHD candidate CTx-1301 will be presented at the AACAP Annual Meeting, highlighting its once-daily, extended-release formulation aimed at improving treatment for ADHD patients.

  • Expert Presentation: Dr. Ann Childress, a leading ADHD specialist, will present the Phase 3 trial results, emphasizing CTx-1301's efficacy and safety in pediatric subjects with ADHD.

  • Innovative Drug Delivery: CTx-1301 utilizes Cingulate's Precision Timed Release™ platform to provide three timed releases of medication throughout the day, addressing limitations of current stimulant therapies.

  • Company Overview: Cingulate Inc. is focused on developing next-generation pharmaceutical products to enhance patient outcomes, with CTx-1301 in late-stage development for ADHD and other candidates targeting anxiety and neuropsychiatric conditions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cingulate Inc (CING) stock price today?

The current price of CING is 3.94 USD — it has decreased -0.25 % in the last trading day.

arrow icon

What is Cingulate Inc (CING)'s business?

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

arrow icon

What is the price predicton of CING Stock?

Wall Street analysts forecast CING stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CING is 12.00 USD with a low forecast of 8.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cingulate Inc (CING)'s revenue for the last quarter?

Cingulate Inc revenue for the last quarter amounts to -6.00M USD, increased 82.68 % YoY.

arrow icon

What is Cingulate Inc (CING)'s earnings per share (EPS) for the last quarter?

Cingulate Inc. EPS for the last quarter amounts to -4244354.00 USD, increased 9.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cingulate Inc (CING)'s fundamentals?

The market is revising No Change the revenue expectations for Cingulate Inc. (CING) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 1.03%.
arrow icon

How many employees does Cingulate Inc (CING). have?

Cingulate Inc (CING) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Cingulate Inc (CING) market cap?

Today CING has the market capitalization of 26.62M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free